Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 19Terminated 8Unknown 7Recruiting 6Withdrawn 3Not yet recruiting 3Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 62Carcinoma, Non-Small-Cell Lung 43Triple Negative Breast Neoplasms 24Ovarian Neoplasms 21Fallopian Tube Neoplasms 17Neoplasm Metastasis 15Lung Neoplasms 15Endometrial Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Stomach Neoplasms 12Esophageal Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 9Neoplasms 8Esophageal Squamous Cell Carcinoma 8Colorectal Neoplasms 8Inflammatory Breast Neoplasms 6Head and Neck Neoplasms 6Carcinoma 6Uterine Cervical Neoplasms 5Melanoma 5Carcinoma, Ovarian Epithelial 5Adenocarcinoma Of Esophagus 5Peritoneal Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Squamous Cell 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Lung Diseases 3

Interventions

Dexamethasone 18Cyclophosphamide 16fludarabine 11pomalidomide 9pembrolizumab 9carfilzomib 9daratumumab 7Rituximab 7Lenalidomide 7Calcium Dobesilate 7fludarabine phosphate 6Cisplatin 6Bortezomib 6Gemcitabine 5venetoclax 4elotuzumab 4isatuximab 3Vincristine 3Radiotherapy 3Prednisone 3Letrozole 3Etoposide 3Doxorubicin 3Cytarabine 3tisagenlecleucel 2selinexor 2ruxolitinib 2palbociclib 2ixazomib 2dexamethasone 21-phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Recurrence × Paclitaxel × Clear all
NCT03315364 2026-04-01

OPTIMAL

Daehwa Pharmaceutical Co., Ltd.

Phase 2/3 Active not recruiting
549 enrolled
Breast

Breast Neoplasms, Recurrence

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting
785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡